Gumetinib has a better therapeutic effect, fast onset of anti-tumor effect, and the objective remission rate and disease control rate of patients is above 50%, but it has not been approved for marketing. Gumetinib is a drug that inhibits MET kinase, and clinically it is currently used for the treatment of non-small cell lung cancer with MET mutations, but it has not yet been approved for marketing. In clinical trials, Gumetinib performs well, both primary patients and treated its objective remission rate and disease control rate reached more than 50%, and its anti-tumor effect has a rapid onset of action, the median response period is 1.4 months. However, Gumetinib is prone to adverse reactions such as peripheral edema, neutropenia, headache, nausea and rash, and a number of patients have stopped taking the drug due to severe adverse reactions. Drugs need to be used under the guidance of a doctor, do not use drugs without authorization to avoid adverse consequences.